DCC-3084 | Deciphera

DCC-3084 is a pan-RAF inhibitor that is designed to broadly inhibit Class I, II, and III BRAF mutations, BRAF fusions, and BRAF/CRAF heterodimers. DCC-3084 is being investigated in a phase 1/2 study designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of DCC-3084 as a single and in combinations in patients with advanced malignancies.